Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions

PLoS Neglected Tropical Diseases

Volumn 6, Issue 6, 2012, Pages

  Valencia, Cristian ^a   Arévalo, Jorge ^a,b   Dujardin, Jean Claude ^c   Llanos Cuentas, Alejandro ^a   Chappuis, François ^d   Zimic, Mirko ^b  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIMONY; IMIQUIMOD; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CONCURRENT INFECTION; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; INFANT; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SKIN LEISHMANIASIS; TREATMENT OUTCOME; DRUG MONITORING; EVALUATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PERU; PRESCHOOL CHILD; SKIN ULCER; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMONY; ANTIPROTOZOAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; INFANT; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PERU; SENSITIVITY AND SPECIFICITY; SKIN ULCER; TREATMENT FAILURE; YOUNG ADULT;

EID: 84863680221     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001656     Document Type: Article

References (24)

1. Organization WH (2004) World Health Report 2004: Changing history.
2. Zulueta AM, Villarroel E, Rodriguez N, Feliciangeli MD, Mazzarri M, et al. (1999) Epidemiologic aspects of American visceral leishmaniasis in an endemic focus in Eastern Venezuela. Am J Trop Med Hyg 61: 945-950.
3. Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG, (1993) Epidemiolgy of cutaneous leishmaniasis in Colombia: A longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J Infect Dis 168: 699-708.
4. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, et al. (1995) Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 182: 1259-1264.
5. Bermudez H, Rojas E, Garcia L, Desjeux P, Dujardin JC, et al. (2006) Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann Trop Med Parasitol 100: 591-600.
6. Palacios R, Osorio LE, Grajalew LF, Ochoa MT, (2001) Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 64: 187-193.
7. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C, (1997) A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 57: 651-655.
8. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, et al. (2007) Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195: 1846-1851.
9. Romero GA, Guerra MV, Paes MG, Macedo VO, (2001) Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65: 456-465.
10. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, et al. (2008) Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 46: 223-231.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE, (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818-829.
12. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
13. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL, (2007) Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis 6: 3.
14. Hadi A, (1994) A Modification of a Method for the Detection of Outlayers in Multivariate Analysis. Journal of the Royal Statistical Society Series B 56: 393-396.
15. Fluss R, Faraggi D, Reiser B, (2005) Estimation of the Youden Index and its associated cutoff point. Biom J 47: 458-472.
16. Unger A, O'Neal S, Machado PR, Guimaraes LH, Morgan DJ, et al. (2009) Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg 80: 574-579.
17. Murray HW, Berman JD, Davies CR, Saravia NG, (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
18. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
19. Keane VP, de Klerk N, Krieng T, Hammond G, Musk AW, (1997) Risk factors for the development of non-response to first-line treatment for tuberculosis in southern Vietnam. Int J Epidemiol 26: 1115-1120.
20. Sampaio MJ, Cavalcanti NV, Alves JG, Filho MJ, Correia JB, (2010) Risk factors for death in children with visceral leishmaniasis. PLoS Negl Trop Dis 4: e877.
21. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH, (2003) Prognostic Factor for Death from Visceral Leishmaniasis in Terezina, Brazil. Infection 31: 174-7.
22. Peters W, Killick-Kendrick R, eds (1987) The leishmaniasis in biology and medicine. Clinical aspects and control. In: Press A, editors. editor. London.
23. Bertho AL, Santiago MA, Coutinho SG, (1994) An experimental model of the production of metastases in murine cutaneous leishmaniasis. J Parasitol 80: 93-99.
24. Davies CR, Llanos-Cuentas EA, Pyke SD, Dye C, (1995) Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect 114: 297-318.